Predicting decline in CIDP patients during IVIg treatment adaptation
Official title: ActiCIDP : Exploratory Study on the Feasibility of Predicting CIDP Patients' Evolution Decline During Intravenous Immunoglobulins Treatment Adaptation.
Run by Centre Hospitalier Universitaire de Liege · NCT06183645 · Data updated 2026-11-12
This study is trying to see if we can predict when people with CIDP might get worse during their IVIg treatment by monitoring their health and daily movements over a year.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 99 Years |
| Sex | All |
| Enrollment | 40 (estimated) |
| Sponsor | Centre Hospitalier Universitaire de Liege Academic / other |
| Locations | 1 site (Liège, Liège) |
| Status | Recruiting |
| Started | August 28, 2023 |
| Main results expected | January 2028 |
| Study ends | January 2028 |
| Registry record updated | February 12, 2025 |
| Trial ID | NCT06183645 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults diagnosed with CIDP who are clinically stable and receiving IVIg treatment.
✕Probably not a fit
Patients with significant cognitive disorders, non-ambulant status, or other autoimmune diseases requiring corticosteroids may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to assess the feasibility of predicting declines in patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) during their treatment with intravenous immunoglobulin (IVIg). Approximately 40 patients will be monitored over a year, with assessments every three months. Participants will undergo clinical examinations and various functional tests, while wearing an innovative device called Actimyo to track their daily movements. The data collected will help understand the relationship between treatment adaptation and patient outcomes.
Why it matters
Potential benefit: If successful, this study could lead to improved monitoring and management strategies for CIDP patients undergoing IVIg treatment.
How similar studies have gone: While similar studies have explored monitoring techniques in CIDP, the specific use of the Actimyo device for this purpose is novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Diagnosed with CIDP or possible CIDP based on 2021 EAN/PNS criteria2. * Treated with IVIg (≤1g/kg/3-8week) * Clinically Stable disease for 3 months (according to treating physician opinion). * No treatment withdrawal failure within 1 year * Age over 18 years Exclusion Criteria: * Significant cognitive or communication disorders * Surgery or serious traumatic injury ≤ 6 months * Non ambulant patient * Current participation to a therapeutic trial * Anti-myeline antibodies (anti-MAG) positive or nodo-paranodopathy * Other autoimmune disease that requires Corticosteroids, IVIg, Plasma Exchange treatment * Pregnancy or breastfeeding * Any other condition that, according to the investigator, could significantly interfere with patient evaluation or safety.
Where it's running
-
CHR Citadelle
Liège, Liège, Belgium Recruiting
Study contacts
- Principal investigator: Margaux Poleur, Dr — CHR Citadelle
- Study coordinator: Laurie Medard
- Email: laurie.medard@citadelle.be
- Phone: 043215584
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
KITE-363 treatment for relapsed or refractory autoimmune neurologic diseases
This study will test whether KITE-363 is safe and can help people with relapsed or treatment-resistant autoimmune neurologic diseases such as MS, CIDP, and myasthenia gravis.
-
Immunoadsorption treatment for chronic inflammatory demyelinating polyneuropathy
This observational study will try immunoadsorption as a next-step treatment for adults with CIDP who do not respond well to IVIg or methylprednisolone.
-
Empasiprubart for adults with CIDP
This study will test whether IV empasiprubart helps improve symptoms and is safe for adults with CIDP, with an initial 24-week randomized comparison to placebo followed by two years of empasiprubart for all participants.
-
Imeroprubart for adults with CIDP
This study will test whether the monoclonal antibody Imeroprubart helps adults with active CIDP who are already on stable immunoglobulin or corticosteroid treatment.
-
Empasiprubart versus IVIg for treating CIDP in adults
This trial tests whether empasiprubart works as well as IVIg and is safe for adults with CIDP who currently benefit from IVIg.
-
Evaluating DNTH103 for treating chronic inflammatory demyelinating polyneuropathy
This study is testing a new treatment called DNTH103 to see if it can help adults with chronic inflammatory demyelinating polyneuropathy feel better and stay safe.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.